Bernardo Goulart on correlations of endpoints in lung cancer immunotherapy trials

The Lancet Oncology in conversation with - A podcast by The Lancet Group

Categories:

Education

Dr Bernardo Goulart (US Food and Drug Administration) discusses his paper on correlations of response rate and progression-free survival with overall survival in immunotherapy trials for metastatic non-small-cell lung cancer. Read the full article: https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(24)00040-8/fulltext?dgcid=buzzsprout_icw_podcast_generic_lanonc Tell us what you thought about this episode Continue this conversation on social! Follow us today at... https://twitter...